Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 136Gynecologic 26Thoracic 4Genitourinary 4Sarcoma 2Other 2Head & Neck 2Gastrointestinal 2Tumor-Agnostic 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Liposarcoma 1Colorectal Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 347pembrolizumab 322Pemetrexed 246Cisplatin 218Paclitaxel 147Nivolumab 138durvalumab 133osimertinib 112Docetaxel 111atezolizumab 109Specimen Handling 91Radiotherapy 87Drug Therapy 85Magnetic Resonance Spectroscopy 77Etoposide 76Radiosurgery 72Gemcitabine 71Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 52cemiplimab 47tislelizumab 44Blood Specimen Collection 40Cetuximab 35Taxes 34Platinum 33Injections 33Biopsy 33Standard of Care 31Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Letrozole × Thoracic × 1 year × Clear all
NCT06120283 2026-05-27

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

BeOne Medicines

Phase 1 Recruiting
399 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04553133 2026-05-06

PF-07104091 as a Single Agent and in Combination Therapy

Pfizer

Phase 2 Active not recruiting
157 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Small Cell Lung Carcinoma

NCT04606446 2026-04-16

KAT6

Pfizer

Phase 2 Recruiting
320 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04557449 2025-10-01

CDK4i

Pfizer

Phase 2 Active not recruiting
362 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Adenocarcinoma of Lung, Breast Neoplasms, Liposarcoma, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡